Search research articles
Contact Us
Filters
Showing results (91-100 of 141) with videos related to
Page
of 15
Sort By:
Gynecologie, Obstetrique & Fertilite
|
July 29, 2008
[Ovarian epithelial dysplasia: myth or reality? Review]
G Chêne, F Penault-Llorca, G Le Bouëdec, et al.
Cancer Chemotherapy and Pharmacology
|
January 27, 2019
A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer
M Campone, T Bachelot, F Penault-Llorca, et al.
Oncogene
|
November 19, 2013
Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy
W Leconet, C Larbouret, T Chardès, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 27, 2001
Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients
B Cutuli, C Cohen-Solal-Le Nir, B De Lafontan, et al.
Breast Cancer Research and Treatment
|
August 13, 1999
Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy
P Viens, J Jacquemier, V J Bardou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 14, 2009
Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer
J Dauplat, G Chene, C Pomel, et al.
British Journal of Cancer
|
March 12, 2009
Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience
B Cutuli, C Lemanski, A Fourquet, et al.
Bulletin Du Cancer
|
February 18, 2010
[Ductal carcinoma in situ of the breast (DCIS). Histopathological features and treatment modalities: analysis of 1,289 cases]
B Cutuli, C Lemanski, A Fourquet, et al.
Histopathology
|
April 10, 2008
Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions
G MacGrogan, L Arnould, I de Mascarel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2012
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study
T André, H Blons, M Mabro, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 141) with videos related to
Sort By:
Page
of 15
Gynecologie, Obstetrique & Fertilite
|
July 29, 2008
[Ovarian epithelial dysplasia: myth or reality? Review]
G Chêne, F Penault-Llorca, G Le Bouëdec, et al.
Cancer Chemotherapy and Pharmacology
|
January 27, 2019
A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer
M Campone, T Bachelot, F Penault-Llorca, et al.
Oncogene
|
November 19, 2013
Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy
W Leconet, C Larbouret, T Chardès, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 27, 2001
Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients
B Cutuli, C Cohen-Solal-Le Nir, B De Lafontan, et al.
Breast Cancer Research and Treatment
|
August 13, 1999
Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy
P Viens, J Jacquemier, V J Bardou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 14, 2009
Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer
J Dauplat, G Chene, C Pomel, et al.
British Journal of Cancer
|
March 12, 2009
Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience
B Cutuli, C Lemanski, A Fourquet, et al.
Bulletin Du Cancer
|
February 18, 2010
[Ductal carcinoma in situ of the breast (DCIS). Histopathological features and treatment modalities: analysis of 1,289 cases]
B Cutuli, C Lemanski, A Fourquet, et al.
Histopathology
|
April 10, 2008
Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions
G MacGrogan, L Arnould, I de Mascarel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2012
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study
T André, H Blons, M Mabro, et al.
Page
of 15